New treatment option for advanced or recurrent endometrial cancer
https://www.facingourrisk.org/XRAY/dostarlimab-Jemperli-for-advanced-endometrial-cancer
Full article: https://www.nejm.org/doi/10.1056/NEJMoa2216334
If you have advanced or recurrent endometrial cancer, there is a new treatment called Jemperli (dostarlimab) that could be an option for you. This study looked at how well Jemperli worked compared to standard treatment. Based on these results, the Food and Drug Administration (FDA) approved the combination of Jemperli and chemotherapy for certain types of advanced endometrial cancer. (Posted 8/4/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is the addition of Jemperli or Keytruda to my treatment an option?
- Does my tumor have any markers (such as, dMMR or MSI-High) that could guide treatment decisions?
- How long does treatment with Jemperli last, and how often would I need to receive it?
- What is the estimated cost of Jemperli treatment? is it covered by my insurance?
- Are there any specific precautions I need to consider when taking Jemperli?
- Can Jemperli interact with any of my other medications or treatments?
- What are the chances of recurrence or progression of my cancer even with the addition of Jemperli?
Open Clinical Trials
The following studies are enrolling people with advanced endometrial cancer.
- NCT04486352: A Study of Targeted Therapies for Patients With Recurrent Endometrial CancerA Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer. This study will test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab in people with recurrent endometrial cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study will evaluate the safety, effectiveness, and tolerability of the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability-high (MSI-H) solid tumors resistant to prior PD-(L)1 therapy.
- NCT03955978: Dostarlimab in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer. The purpose of this study is to evaluate dostarlimab compared to standard-of-care radiation therapy for patients with inoperable endometrial cancer to establish the safety and efficacy of inducing an anti-tumor immune response.
- NCT04463771: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204). This is a Phase 2 study of the PD-1 antibody retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy.
A number of other clinical trials for patients with endometrial cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.